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Abstract. Vascular endothelial growth inhibitor (VEGI) has 
been associated with tumor-related vasculature in certain 
malignancies. However, its implication in renal cell carcinoma 
(RCC), an angiogenesis-dependent tumor, remains unknown. 
In the present study, we investigated the role played by VEGI 
in RCC. The expression of VEGI was examined in human 
renal tissue and RCC cell lines using immunohistochemical 
staining and RT-PCR, respectively. The biological impact of 
modifying the expression of VEGI in RCC cells was evalu-
ated using in vitro and in vivo models. We show that VEGI 
mRNA is expressed in a wide variety of human RCC cell 
lines, all of normal renal and most of RCC tissue specimens. 
VEGI protein expression was observed in normal renal 
tubular epithelial cells, but was decreased or absent in RCC 
specimens, particularly in tumors with high grade. Moreover, 
forced expression of VEGI led to an inhibition of vascular 
endothelial tube formation, decrease in the motility and adhe-
sion of RCC cells in vitro. Interestingly, forced expression 
of VEGI had no bearing on growth, apoptosis and invasive 
capacity of RCC cells. However, tumor growth was reduced 
in xenograft models. Immunohistochemical staining showed 
that microvessel density decreased in VEGI forced expression 
xenograft tumor samples. Taken together, our findings showed 
that the expression of VEGI is decreased in RCC, particularly 
in tumors with higher grade. Together with its inhibitory 
effect on cellular motility, adhesion, vascular endothelial tube 
formation and tumor growth in vivo, this suggests that VEGI 
functions mainly through inhibition of angiogenesis and is a 
negative regulator of aggressiveness during the development 
and progression of RCC.
Introduction
Renal cell carcinoma (RCC), which accounts for ~2-3% of all 
adult malignant neoplasm, is the most lethal of the common 
urologic cancers (1,2). Traditionally, 30-40% of patients with 
RCC die of their cancer, in contrast to the 20% mortality 
rates associated with prostate and bladder carcinomas (3,4). 
Over the past three decades, there has been an increase in the 
detection of renal tumors due to the widespread use of non-
invasive imaging techniques such as ultrasound and computed 
tomography scan in the investigation of various non-specific 
symptoms (5). This trend has correlated with an increased 
proportion of incidentally discovered and localized tumors 
and with improved 5-year survival rates for patients with 
this stage of disease (6,7). However, other factors must also 
be at play because Chow and colleagues have documented a 
steadily increasing mortality rate from RCC per unit popula-
tion since the 1980s and this was observed in all ethnic and 
both gerders (3,8). It has been reported that the incidence 
of advanced tumors per unit population has also increased; 
and the mortality rate per unit population has still been 
negatively affected (3,8-10). In the European Union and the 
United States, between 46,000 and 63,000 new cases of RCC 
are diagnosed annually and ~40% of RCC patients die from 
RCC-related causes each year (7). In the treatment of renal cell 
carcinoma, localized disease is curable by surgery, however, 
metastatic and locally advanced disease are considerably more 
difficult to treat (11,12). Historically, therapeutic options for 
metastatic or for locally advanced RCC, primarily cytokine 
therapy, produced low response rates and considerable toxicity 
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(13,14). Moreover, it is well known that RCC is one of the most 
vascular of cancers as reflected by the distinctive neovascular 
pattern exhibited on renal angiography. Given the dependence 
of RCC on angiogenesis and the absence of generally effective 
forms of systemic therapies, it is not surprising that RCC has 
been targeted for anti-angiogenic approaches. Targeted agents 
(such as sorafenib, sunitinib malate, pazopanib, bevacizumab) 
are now well established for the treatment of patients with 
advanced or metastatic renal cell carcinoma (7,15,16).
Although the targeted therapy is spread among a variety 
of new active drugs, so far complete cure is achieved very 
rarely (17). Experience has shown that the targeted therapies 
control tumor growth only temporarily and after a latency 
period that may vary according to the molecular character-
istics of the tumor, the malignancy reappears. Resistance to 
targeted therapy may be caused by activation of alternative 
proangiogenic pathways, recruitment of bone marrow-derived 
proangiogenic cells, increased pericyte coverage of tumor 
vasculature and enhancement of invasion and metastasis 
(18-20). Additionally, host genomics may adversely affect drug 
metabolism, leading to poor activity or toxicities. However, 
there does not appear to be cross-resistance among these 
therapies and subsequent treatment lines can be beneficial. 
Therefore, finding a new target for anti-angiogenesis could be 
helpful for treating advanced and metastatic RCC (16).
Vascular endothelial growth inhibitor (VEGI) [also known 
as tumor necrosis factor superfamily member 15 (TNFSF15) 
and TNF ligand related molecule 1 (TL1)], a natural anti-
angiogenic factor, was first reported in 1999 from human 
umbilical vein endothelial cells (21-23). The full gene of VEGI 
is ~17 kb, which consists of four exons and three introns and 
is mapped to human chromosome 9q32. Three splicing vari-
ants of VEGI have been reported. Its transcript was found to 
be expressed in the placenta, lung, kidney, skeletal muscle, 
pancreas, spleen, small intestine, prostate and colon (23). The 
secreted soluble form of VEGI has been demonstrated as a 
potent anti-angiogenic factor through inhibiting proliferation 
of endothelial cells (24,25). Previous studies have also shown 
that VEGI expression could significantly reduce motility 
and adhesion of prostate and bladder cancer cells (26,27). 
Zhai et al and Xiao et al reported that VEGI markedly 
suppressed the growth of colon carcinoma cells (murine colon 
cancer cells, MC-38) both in vitro and in vivo (23,28). Systemic 
administration of VEGI also markedly inhibited tumor 
growth and increased survival time in a Lewis lung cancer 
(LLC) murine tumor model suggesting that pro-apoptotic 
effect of soluble VEGI in endothelial cells is critical for its 
antitumor activity (28-32).
Despite these observations of VEGI in solid tumors, 
its role in RCC remains unknown. In the present study, the 
expression of VEGI was examined in human RCC and normal 
renal tissues and in RCC cell lines. The biological function of 
this molecule was investigated in vitro and in vivo, in which 
the expression of VEGI was manipulated by genetic methods.
Materials and methods
Materials
Mice. All female BALB/c mice (6-8 weeks, 18-22 g) were 
supplied by Shanghai Laboratory Animal Center [SLAC, 
Shanghai, China, Animal Certificate No. SCXK (Hu) 
2007-0005]. All the procedures related to animal handling, 
care and the treatment in this study were performed according 
to the guidelines approved by the Institutional Animal Care 
and Use Committee (IACUC) of CrownBio following the 
guidance of the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC).
Cell lines. All cell lines used in this study were purchased from 
the American Type Culture Collection (ATCC, Rockville, 
MD, USA). This study used human renal cell carcinoma cells 
(786-O, OS-RC-2, A-498, Caki-1), a human adrenal gland 
small cell carcinoma cell line (SW-13) and a human umbilical 
vein endothelial cell line (HUVEC). Cells were routinely 
cultured with Dubecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum, penicillin and strep-
tomycin (Gibco BRC, Paisley, UK).
Human renal cell carcinoma specimens. A total of 23 pairs 
renal cell carcinoma and normal renal tissue samples were 
snap-frozen in liquid nitrogen immediately after open radical 
nephrectomy. The pathologist verified normal and cancer 
specimens. All protocols were reviewed and approved by the 
local ethics committee and all patients gave written informed 
consent.
RNA isolation and reverse transcription PCR. RNA was 
isolated using Total RNA Isolation reagent (ABgene, Epsom, 
UK). First strand cDNA was synthesized from 0.5 µg RNA 
using a reverse transcription kit (Sigma, Poole, Dorset, UK). 
The quality of cDNA was verified through the amplification and 
detection of the GAPDH housekeeping gene. VEGI forward 
and reverse primers (Table I) were designed based on the 
human VEGI sequence (GeneBank accession no. BD131562). 
PCR was performed in a GeneAmp PCR system 2400 thermo-
cycler (Perkin-Elmer, Norwalk, CT, USA). Conditions for PCR 
were 40 sec at 94˚C, 60 sec at 55˚C, 60 sec at 72˚C (35 cycles). 
PCR products were separated on a 1.4% agarose gel.
IHC staining of human renal and xenograft tumor specimens. 
Frozen specimens of renal cell carcinoma (n=23), normal 
renal tissue (n=23) and xenograft tumors (n=24) were cut at 
a thickness of 6 µm using a cryostat (Leica CM 1900, Leica 
Microsystems UK Ltd., Buckinghamshire, UK). The nature of 
the samples was independently verified by two pathologists. 
After fixation, the sections were blocked with horse serum 
and probed with or without VEGI antibody (SC-53975) for 
1 h. The secondary biotinylated antibody and the avidin-biotin 
complex were subsequently applied to detect VEGI expres-
sion in accordance with the Vectastain Universal Elite ABC 
kit protocol (Vector Laboratories, Peterborough, UK). After 
developing color with DAB, the sections were counterstained 
with Gill's hematoxylin. Staining was independently assessed 
by the authors. The monoclonal mouse anti-human-VEGI and 
anti-human-VEGFR2 antibodies were purchased from LSBio 
Inc. (LS-C76815 and LS-C92359, respectively, LSBio Inc., 
Seattle, WA, USA). Monoclonal mouse anti-human-Ki67 and 
anti-human-CD31 (PECAM) antibodies were purchased from 
Santa Cruz Biotechnology, Inc. (SC-56320 and SC-133091 
respectively, Santa Cruz, CA, USA).
INTERNATIONAL JOURNAL OF ONCOLOGY  42:  1664-1673,  20131666
Western blot analysis of VEGI expression. Protein concentra-
tion in cell lysates were determined using the DC Protein Assay 
kit (Bio-Rad) and an ELx800 spectrophotometer (Bio-Tek™). 
Equal amount of proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
blotted onto nitrocellulose sheets. Proteins were then probed 
with the VEGI antibody (1:1,500) and peroxidase-conjugated 
secondary antibodies. Monoclonal mouse anti-human-β-actin 
(1:1,000, SC-130301, Santa Cruz) was used as a housekeeping 
control. Protein bands were visualized using the Supersignal™ 
West Dura system (Pierce Biotechnology, Inc., Rockford, IL, 
USA) and photographed using an UVITech imager (UVITech, 
Inc., Cambridge, UK).
Construction of VEGI expressing and ribosome transgenes 
and transfection. The full-length human VEGI coding 
sequence and hammer-head ribozymes targeting human 
VEGI was cloned into a mammalian expression plasmid 
vector (pEF/His TOPO TA, Invitrogen, Inc., Paisley, UK). 
Full primer sequences are provided in Table I. The recom-
binant plasmid vectors were transformed into chemically 
competent TOP10 E. coli (Invitrogen). After verification and 
amplification, empty control plasmids or plasmids containing 
VEGI expression sequence or ribozyme transgenes were then 
transfected into 786-O, SW-13 and SC-OR-2 cells using elec-
troporation (Easyjet, EquiBio Ltd., Kent, UK). After selection 
with blasticidin, the transfectants were used used for subse-
quent analysis.
Real-time quantitative polymerase chain reaction (qPCR). 
Real-time quantitative PCR was carried out using the iCycleriQ5 
system (Bio-Rad, Hemel Hemstead, UK) to determine the 
level of expression of the VEGI transcripts in the cell lines. 
GAPDH was used as a housekeeping control.
Cell growth assay. This was based on a method we previously 
described (33). Briefly, cells were plated into a 96-well plate 
(2,500 cells/well). Cell growth was assessed after 1, 3 and 
5 days. Crystal violet was used to stain cells and absorbance 
was determined at a wavelength of 540 nm using a spectropho-
tometer (Bio-Tek, Elx800, UK).
Flow cytometric analysis of apoptosis. All cells including 
those floating in the culture medium were harvested after a 
period of incubation. The apoptotic population of the cells was 
determined using Vybrant® Apoptosis Assay kit (Invitrogen) 
and flow cytometry (CyFlow® SL, Partec GmbH, Münster, 
Germany).
Wounding assay. The migration of cells in a monolayer across 
a wounded surface of a near-confluent cell monolayer was 
examined. Cells at a density of 50,000/well were seeded into 
a chamber slide and allowed to reach near confluence. The 
monolayer of cells was then scraped with a fine gauge needle 
to create a wound of ~200 µm. The movement of cells to close 
the wound was recorded using a time lapse video recorder 
and analysed using the motion analysis feature of the Image J 
software (NIH, USA).
Motility assay using Cytodex-2 beads. Cells (1x106) were 
incubated with 100 µl of cytocarrier beads overnight. The 
beads were washed twice to remove dead cells and then resus-
pended. Beads/cells (100 µl) were transferred into each well of 
a 24-well plate. After incubation for 4 h, the cells were fixed 
in 4% formalin and stained with 0.5% crystal violet before 
counting.
Invasion assay. This was modified from a method we 
prevously described (33). Transwell inserts with 8-µm pore 
Table I. Primer sequences for PCR.
Primer Forward Reverse
hGAPDH 5'-AGCTTGTCATCAATGGAAAT-3' 5'-CTTCACCACCTTCTTGATGT-3'
hGAPDH (qPCR) 5'-CTGAGTACGTCGTGGAGTC-3' 5'-ACTGAACCTGACCGTACA
  CAGAGATGATGACCCTTTTG-3'
  Z-sequence
VEGI 5'-ATGAGACGCTTTTTAAGCAA-3' 5'-CTATAGTAAGAAGGCTCCAAAG-3'
VEGI (qPCR) 5'-CAAAGTCTACAGTTTCCCAAT-3' 5'-ACTGAACCTGACCGTACA
  TGATTTTTAAAGTGCTGTGTG-3'
  Z-sequence
VEGI (ribozyme 2) 5'-CTGCAGTCTCACAACTGGAAACT 5'-ACTAGTTAATCCTCTTTCTTGTTT
 GATGAGTCCGTGAGGA-3' CGTCCTCACGGACT-3'
VEGI (expression) 5'-ATGAGACGCTTTTTAAGCAA-3' 5'-CTATAGTAAGAAGGCTCCAAAGA-3'
Primers for T7F: TAATACGACTCACTATAGGG BGHR: TAGAAGGCACAGTCGAGG
detecting plasmid
Primers to RBTPF: CTGATGAGTCCGTGAGGACGAA RBBMR: TTCGTCCTCACGGACTCATCAG
detect ribozymes 
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size were coated with 50 µg Matrigel (BD Matrigel™ base-
ment membrane matrix) and air-dried. After rehydration, 
20,000 cells were added to each well. After 96 h cells that 
had migrated through the matrix to the other side of the 
insert were fixed, stained and then counted under a micro-
scope.
Cell-matrix adhesion assay. Cell-matrix adhesion was assessed 
in a standard manner. Cells (40,000) were added in each well 
of 96-well plate, previously coated with Matrigel (5 µg/well). 
After 40 min of incubation, non-adherent cells were washed 
off using BSS buffer. The remaining adherent cells were then 
fixed and stained with crystal violet. The number of adherent 
cells was then counted.
Endothelial cell differentiation assay: tube formation on 
Matrigel (34). This was based on a Matrigel-sandwich tubule 
forming assay developed in our laboratory. Briefly, 200 µg of 
cold Matrigel solution dispersed in 100 µl (Becton-Dickinson, 
Bristol, UK) was added to a 96-well plate and allowed to 
air-dry at 37˚C. Following rehydration of Matrigel, it formed 
a thin bottom layer. HUVEC cells (2.5x104) per well were 
seeded onto a 96-well plate and allowed to attach to the bottom 
of the well (4-6 h). After that, 200 µg of cold Matrigel solution 
dispersed in 100 µl was loaded to each well again, followed by 
incubation at 37˚C for 3 h when the second layer of Matrigel 
solidified. Finally, 10,000 tested cells (different renal cell 
carcinoma cell lines) were added and incubated at 37˚C in a 
humidified chamber with 5% CO2. Following incubation for 
7 or 20 h, cultures were observed and photographed (Nikon, 
Tokyo, Japan).
Tumor xenografts in Nu/Nu nude mice. Twenty-four mice 
were divided into three groups (786-Owt Group, 786-OpEF/His 
Group and 786-OVEGIexp4 Group). Each mouse was inoculated 
subcutaneously at the right flank with 786-O cells (5x106) in 
0.1 ml of PBS for tumor development. The mice were kept 
in individually ventilated cage (IVC) systems at constant 
temperature and humidity with 4 animals in each cage. The 
date of tumor cell inoculation was denoted as day 0. The data 
of tumor growth and normal behavior such as mobility, visual 
estimation of food and water consumption, body weight gain/
loss (body weights were measured twice weekly), eye/hair 
matting and any other abnormal effect were collected every 
three days. Tumor sizes were measured each three days in two 
dimensions using a caliper and the volume was expressed in 
mm3 using the formula: V = 0.5 a x b2 where a and b were the 
long and short diameters of the tumor, respectively.
Statistical analysis and software. The mean optical density 
(MOD) feature of RT-PCR and western blot analysis was 
analysed using software package Image-Pro Plus 6.0 (Media 
Cybernetics, USA). The method was as follows: every 
image prepared for comparison was changed to grayscale 
image. Then, selecting ten points in the comparison region 
randomly, the MOD of the point was analyzed using the 
software. The length of cell migration and HUVEC was 
measured by software Image J (NIH). The distance of 
HUVEC cells was calculated along the long axes in each 
compared image.
All statistical analysis was performed using the SPSS 16.0 
software. Two sample t-tests was used for normally distributed 
data. Fisher's exact test was used for analyzing immunohisto-
chemical staining in renal tissues. Differences were considered 
to be statistically significant at P<0.05.
Results
The expression of VEGI in renal cell carcinoma cell lines 
and renal tissues. The expression of VEGI was examined in 
four renal cell carcinoma cell lines, adrenal gland cell line and 
human renal tissues using conventional RT-PCR. VEGI tran-
script was detectable in all five cell lines (Fig. 1A). It was also 
detected more frequently in normal renal tissues (23/23) than 
that in renal cell carcinoma tissues (15/23), P<0.01 (Fig. 1B). 
Moreover, the expression of VEGI transcript was stronger in 
normal renal tissues (MOD=0.87±0.13) than that in renal cell 
carcinoma tissues (MOD=0.24±0.17), P<0.01. Furthermore, in 
immunohistochemical staining, VEGI was seen in normal 
renal tubular epithelia cells, but the staining was decreased 
or absent in renal cell carcinoma cells, particularly in the 
specimen with higher grade (Fig. 1C). The positive staining 
of normal tissue (100%, 23/23) was significantly higher than 
that of renal cell carcinoma tissues (34.78%, 8/23), P<0.01. 
The MOD of normal renal tissues (0.49±0.15) was higher than 
that of renal cell carcinoma tissues (0.11±0.05) either, P<0.01.
Genetic manipulation of VEGI levels in RCC cell lines. 
786-O, which expressed modest level of VEGI transcript, were 
transfected with a VEGI expression construct and anti-VEGI 
ribozyme transgenes, to respectively create sublines showing 
enhanced or suppressed levels of VEGI expression. OS-RC-2 
and SW-13, which expressed lower level of VEGI transcript, 
was only transfected with the VEGI expression construct. As 
shown by RT-PCR analysis, VEGI mRNA expression was 
increased in 786-OVEGIexp4, OS-RC-2VEGIexp4 and SW-13VEGIexp4 
cells, compared to wild-type (786-Owt, OS-RC-2wt and SW-13wt) 
and plasmid control (786-OpEF/His, OS-RC-2pEF/His and SW-13pEF/
His) cells (Fig. 2A). However, VEGI mRNA expression in the 
786-OVEGIrib2 cells was lower than that in 786-Owt cells, but was 
similar to that in 786-OpEF/His cells, suggesting that the ribozyme 
is ineffective (Fig. 2A). Moreover, according to the results of 
qPCR, VEGI mRNA expression was dramatically increased in 
786-OVEGIexp4, OS-RC-2VEGIexp4 and SW-13VEGIexp4 cells, but did 
not decrease in 786-OVEGIrib2 cells, compared with corresponding 
controls (Fig. 2B). Comparing with controls, an increase in 
the VEGI protein level was also seen in 786-OVEGIexp4 cells in 
western blot analysis (Fig. 2C). However, there was no signifi-
cant difference in VEGI protein level between SW-13VEGIexp4 and 
OS-RC-2VEGIexp4 cells and their controls. Therefore, we chose the 
786-O cell lines to perform our following test.
Manipulation of VEGI expression had no impact on growth, 
apoptosis and invasiveness of RCC cells. First, we examined 
the effect on growth, apoptosis and invasiveness of 786-O cell 
lines by VEGI. The growth (Fig. 3A) and invasion (Fig. 3B) of 
786-OVEGIexp4 cells did not show any difference from that of wild-
type and empty plasmid control cells (P>0.05). Furthermore, we 
did not find a difference in the apoptotic populations between cells 
with VEGI forced expression and control cells (P>0.05) (Fig. 3C).
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Figure 1. VEGI expression in renal tissues and cell lines. (A) Detection of the VEGI transcript using RT-PCR in five cell lines. (B) Detection of the VEGI 
transcript in a panel of tumor and normal renal tissues. GAPDH was used as the house-keeping control. N, normal. T, tumor. (C) Immunohistochemical 
staining of human renal specimens. (a) Normal renal tissues. The VEGI protein was found to be intensively stained in the cytoplasmic area of normal renal 
tubular epithelia cells. (b) Renal cell carcinoma tissues with nuclear grade 1. VEGI was weakly stained in these cells than those in normal cells. (c) Renal cell 
carcinoma tissues with nuclear grade 2. VEGI was weakly stained in these cells. (d) Renal cell carcinoma tissues with nuclear grade 3. The VEGI protein 
staining was nearly absent. That is, VEGI expression was seen to be negative or weakly positive in the cancer cells of renal cell carcinoma tissue.
Figure 2. Confirmation of manipulation of VEGI expression in renal cell carcinoma cells. (A) Verification of forced expression of the VEGI transcript in 786-O, 
SW-13 and OS-RC-2 cells. VEGI mRNA expression in the 786-OVEGIrib2 cells was lower than that in 786-Owt cell, but was similar to that in 786-OpEF/His cells, 
suggesting that the ribozyme is ineffective. Representative image from 4 experiments show results of the RT-PCR. (B) Verification of forced expression of 
VEGI transcript in 786-O, SW-13 and OS-RC-2 cells, using Q-PCR. VEGI mRNA expression was dramatically increased in 786-OVEGIexp4, OS-RC-2VEGIexp4 and 
SW-13VEGIexp4 cells, but did not decrease in 786-OVEGIrib2 cells, compared with the wild-type and empty plasmid control cells. The error bars represent standard 
deviations. (C) Force expression of VEGI at protein level using western blot analysis for 786-O, SW-13 and OS-RC-2 cells. VEGI protein level was increased in 
786-OVEGIexp4 cells compared to that of wild-type and empty plasmid control cells. However, there was no significant difference in VEGI protein level between 
SW-13VEGIexp4 and OS-RC-2VEGIexp4 cells and their controls.
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Figure 3. The effect of VEGI forced expression on growth, invasiveness and apoptosis of 786-O cells. (A) The growth capacity of 786-OVEGIexp4 cells did not 
show any difference from that of wild-type and empty plasmid control cells (P>0.05). (B) The invasiveness of 786-OVEGIexp4 cells did not show any difference 
from that of wild-type and empty plasmid control cells (P>0.05). (C) There was no difference in the apoptotic populations between cells with VEGI forced 
expression and control cells (P>0.05). The error bars represent standard deviations.
Figure 4. The effect of VEGI forced expression on cell matrix adhesion, migration and vascular endothelial tube formation. (A) VEGI expression and in vitro 
cell-matrix adhesion. All experiments were repeated 5 times. Forced expression of VEGI reduced the number of adherent cells in 786-OVEGIexp4 cells (P<0.01). 
Error bars represent the SD. (B) The effect of forced expression of VEGI on migration of 786-OVEGIexp4 cells. All experiments were repeated 4 times. The 
motility of 786-OVEGIexp4 cells was markedly reduced, compared with wild-type and empty plasmid control cells (P<0.01). Experiments were done in 6-wells 
per cell type. Error bars represent the SD. (C) The effect of forced expression of VEGI on migration assay (scratch wounding assay). All experiments were 
repeated 3 times. The movement was reduced significantly in 786-OVEGIexp4 cells compared with wild-type and empty plasmid control cells (P<0.01). Error 
bars represent the SD. (D) The effect of forced expression of VEGI on vascular endothelial tube formation. Compared to controls, when HUVECs with 
786-OVEGIexp4 were co-cultured, the tube formation decreased significantly. The cells collected together showing poor ductibility.
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The influence of VEGI expression on cell matrix adhesion 
and motility of 786-O cells. In this step, we examined the 
effect on cell-matrix adhesion of 786-O cell lines by VEGI. 
Overexpression of VEGI exhibited a significant inhibitory 
effect on cell-matrix adhesion of the cells. Compared with 
786-Owt (26.84±5.19) and 786-OpEF/His (24.72±7.01), the 
number of adherent cells for 786-OVEGIexp4 (11.13±4.88) was 
significantly reduced (P<0.001 vs both controls) (Fig. 4A).
In the cytocarrier based cell motility assay, we found that 
cell motility was reduced significantly in 786-OVEGIexp4 cells. 
The number of migrating 786-OVEGIexp4 cells was 18.92±6.88 
compared with 48.31±9.19 for 786-Owt cells and 43.97±7.01 for 
786-OpEF/His cells (Fig. 4B) (both P<0.01). To further investi-
gate the effect of forced expression of VEGI on cell motility, 
wounding assay was used. We also found that the motility was 
reduced significantly in cells containing the VEGI expression 
construct. The average migrating distance of 786-OVEGIexp4 
was 43.35±19.65 µm, P<0.01 compared to both 786-Owt 
(102.39±27.42 µm) and 786-OpEF/His (118.71±31.81 µm) cells 
(Fig. 4C).
Inhibition of vascular endothelial tube formation by forced 
expression of VEGI. Single HUVECs, when cultured between 
the Matrigel layers, were seen to form typical tube-like struc-
tures after 20 h. Fig. 4D shows that the lumen was composed of 
several endothelial cells linked to each other. When HUVECs 
with 786-Owt/786-OpEF/His were co-cultured, a proportion of 
cells formed an incomplete lumen. The cells still had suffi-
Figure 5. The effect of VEGI forced expression on xenograft models and angiogenesis in xenograft models. (A) The effect of forced expression of VEGI on 
xenograft models. Three weeks after successful establishment of xenograft models, tumor volume was found significantly reduced in the group of BALB/c 
nude mice injected with 786-OVEGIexp4 cells, compared with 786-Owt, 786-OpEF/His cells (P<0.01). Error bars represent the SD. (B) The effect of VEGI forced 
expression on angiogenesis in xenograft models. In IHC, comparing with 786-Owt and 786-OpEF/His cells, VEGI staining was increased in samples from 
xenograft tumors with 786-OVEGIexp4 cells (P<0.01). However, comparing with 786-Owt and 786-OpEF/His cells, Ki67 and VEGFR2 expression was decreased, 
respectively, in tumors with 786-OVEGIexp4 cells (P<0.01). Significant reduction in microvessel density, as indicated by reduced CD31 staining, was observed in 
786-OVEGIexp4 tumors compared to that in 786-Owt and 786-OpEF/His tumors (P<0.01). 
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cient ductibility. However, when HUVECs with 786-OVEGIexp4 
co-cultured, the tube formation decreased significantly 
in comparison with controls (Fig. 4D). The cells collected 
together with poor ductibility. The distance of HUVECs in 
each field co-cultured with 786-OVEGIexp4 (1.29E-04±5.5E-06) 
was significantly decreased, compared with HUVECs 
co-cultured with 786-Owt/786-OpEF/His and HUVECs only 
(2.44E-04±9.1E-06, 2.48E-04±9.9E-06, 2.58E-04±1.8E-06, 
respectively) (P<0.01).
Reduced tumor growth in xenograft models from 786-O cells 
with forced expression of VEGI. To examine the effect of 
VEGI on tumor growth, xenograt models were successfully 
established in BALB/c nude mice by subcutaneous injection 
of 786-Owt, 786-OpEF/His and 786-OVEGIexp4 cells. Tumor volume 
was found significantly reduced in the group of BALB/c 
nude mice injected with 786-OVEGIexp4 cells (216±146 mm2), 
compared with 786-Owt, 786-OpEF/His cells (473±298 and 
475±115 mm2, respectively), P<0.01 (Fig. 5A).
Reduced angiogenesis in xenograft models from 786-O cells 
with forced expression of VEGI. In immunohistochemical 
staining with samples from xenograft tumor, comparing with 
786-Owt and 786-OpEF/His cells, VEGI staining was increased 
in tumors with 786-OVEGIexp4 cells (MOD was 0.45±0.22, 
0.39±0.15 and 0.67±0.19, respectively, P<0.01) (Fig. 5B). 
Significant reduction in microvessel density, as indicated by 
reduced CD31 staining, was observed in 786-OVEGIexp4 tumors 
compared to that in 786-Owt and 786-OpEF/His tumors (87±21, 
211±43 and 189±33 respectively, P<0.01) (Fig. 5B). Moreover, 
comparing with 786-Owt and 786-OpEF/His tumors, Ki67 
(284±41, 331±29 and 119±37, P<0.01) and VEGFR2 (377±41, 
321±29 and 144±24, P<0.01) expression were also decreased 
in 786-OVEGIexp4 tumors (Fig. 5B).
Discussion
VEGI, first identified from human umbilical vein endothelial 
cells is known to exist abundantly in arterial endothelial 
cells (21,22). Subsequently, it has been reported that VEGI 
is also expressed in a wide variety of human cancer cell 
lines, including breast, prostate, bladder, colorectal and liver 
(24,35-38). The role of VEGI in human cancer cells has been 
investigated. According to the literature, it is able to induce 
apoptosis in endothelial cells via an autocrine pathway 
(22-25). Overexpression of VEGI has been shown to inhibit 
tumor neovascularisation and progression in cellular and 
animal models. Chew et al reported that overexpression of 
VEGI induced apoptosis in endothelial cells and inhibited the 
growth of xenograft tumors, together with a reduction in the 
microvessel density (24). Zhai et al found that the recombinant 
VEGI protein could markedly inhibit the growth of breast and 
colon xenograft tumors and suggested that the effect may be 
through an indirect inhibition on capillary-like structures and 
cells growth (23). Hou et al, using a Lewis lung cancer (LLC) 
murine tumor model, demonstrated that systemic administra-
tion of VEGI gave rise to a marked inhibition of tumor growth 
and to an increase in survival time of the treated animals 
(29). Further investigation has shown that the density of the 
endothelial cells exhibited an 88% decrease within 1 week 
of treatment with recombinant human VEGI and a further 
decrease within 3 weeks in Lewis lung cancer murine tumor 
models. Parr et al reported that patients with breast tumors 
expressing reduced levels of VEGI had a higher local recur-
rence, shorter survival time and an overall poorer prognosis 
than those patients expressing high levels of VEGI (39). 
Chen et al also reported that purified rhVEGI-192 potently 
inhibited endothelial growth, induced endothelial apoptosis 
and suppressed neovascularization in chicken chorioallantoic 
membrane and demonstrated that VEGI-192 is capable of 
forming polymeric structure, which is possibly required for its 
anti-angiogenic activity (40). Liang et al reported that VEGI 
inhibits bone marrow (BM)-derived endothelial progenitor 
cells (EPC) mobilization and prevents their incorporation into 
LLC tumors by inducing apoptosis specifically of BM-derived 
cells, resulting in the inhibition of EPC-supported tumor vascu-
logenesis and tumor growth (41). Overall, the above evidence 
indicated that the antitumor activity of VEGI is more likely to 
be the result of an interference with the development of tumor 
associated vasculature. However, many reports have also 
suggested that VEGI may inhibit the growth of some human 
tumor cell lines, including human histiocytic lymphomas 
(U-937), human breast carcinomas (MCF-7), human epithelial 
carcinoma (HeLa) and human myeloid lymphomas ML-1a 
(28,42). Our previous results also show that the overexpres-
sion of VEGI can directly affect the motility and adhesion of 
urothelial tumor and prostate cancer cells (26,27).
Given the dependence of RCC on angiogenesis and the 
mechanisms of target therapy, it is speculated that VEGI 
may be an effective target in treating RCC. The present study 
demonstrated exciting evidence supporting our hypothesis.
First of all, VEGI mRNA was expressed in a wide variety 
of human RCC cell lines, all the normal renal specimens 
and a proportion of the RCC specimens. It is obviously that 
VEGI transcript expression is at lower level in RCC tissues 
than that in normal renal tissues. The immunohistochemical 
analysis clearly indicates a similar trend. VEGI protein was 
found to be expressed at lower level in RCC tissues than that 
in normal renal tissues and was almost absent in tumors with 
high grade. The absence or reduction of tumor VEGI expres-
sion suggests that there may be a shift in the balance between 
pro- and anti-angiogenic stimuli. This loss of balance may 
subsequently produce a microenvironment that is conducive to 
tumor growth and survival.
Moreover, our results confirm that forced-expression 
of VEGI was able to directly affect the motility and adhe-
sion of 786-O cells. The number of adherent cells in VEGI 
forced-expression cells was >50% decreased compared with 
the wild-type cells. The average distance of VEGI expression 
cells was also decreased dramatically compared with controls. 
Therefore, VEGI can directly reduce aggressiveness of renal 
cancer cells, which is in line with the decreased expression of 
VEGI in RCC specimens.
Our results demonstrated that force expression VEGI 
suppressed renal cell carcinoma growth in vivo. Comparing 
with controls, tumor volume was reduced >50% in the group of 
BALB/c nude mice injected with 786-OVEGIexp4 cells. However, 
manipulation of VEGI expression had no impact on growth, 
or apoptosis of RCC cells in vitro. Combined with the result 
of endothelial cell differentiation assay (tube formation on 
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Matrigel), when HUVECs with 786-OVEGIexp4 were co-cultured, 
the tube formation decreased significantly in comparison with 
controls. As indicated by reduced CD31 staining, significant 
reduction in microvessel density was observed in xenograft 
tumor samples. All the above suggested that the anti-RCC 
growth in vivo of force expression VEGI is more likely to be 
the result of an interference with the development of tumor 
associated vasculature than that of a direct effect on tumor 
cells.
The present study also shows that Ki67 and VEGFR2 
protein level was decreased significantly in 786-OVEGIexp4 
tumors. It is well known that the Ki-67 protein (also known 
as MKI67) is a cellular marker for proliferation (43-45). Its 
high expression may be independently associated with an 
increased risk of poor disease-free survival for many tumors. 
Its decrease shows that 786-OVEGIexp4 cell proliferation was 
inhibited in vivo. Probably, this kind of inhibition was 
also dependent on suppressed vasculogenesis. The VEGF/
VEGFR2 pathway plays a central role in tumor vasculature. 
Blocking it may achieve inhibition of the growth and metas-
tasis of RCC (46,47). VEGFR2 protein level decreased in 
786-OVEGIexp4 tumors indicating that VEGI suppressed angio-
genesis through VEGF/VEGFR2 pathway except for DR3, 
SAPK/JNK and p38 MAPK and caspase pathway (48,49). 
This is a new pathway of VEGI to suppress angiogenesis not 
reported before. It is suggested that reducing tumor neovas-
cularisation and tumor cell proliferation rate may be the 
reason for VEGI suppressing tumor growth in the xenograft 
model.
In conclusion, the present study shows that VEGI expres-
sion is decreased in renal cell carcinoma, particularly in 
tumors with higher grade. VEGI, a potential cell migration 
and adhesion regulating protein of TNFSF, suppressed tumor 
growth in vivo. This is likely via its inhibitory role on anti-
angiogenesis, cell migration and adhesion. Our results suggest 
that VEGI may be a putative tumor suppressor and a potential 
therapeutic target for RCC.
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